Evidence map›Paper›PMID 29456873›Full record

ArticleJournal of clinical and translational science2017

The Rockefeller University Clinical Scholars (KL2) Program 2006-2016.

Sarah J Schlesinger, Michelle Romanick, Jonathan N Tobin, Donna Brassil, Rhonda G Kost, Rita Devine, Barbara O'Sullivan, Roger D Vaughan, Yupu Liang, Joel Correa da Rosa and 3 more

Abstract read
In one paragraph

Article in Journal of clinical and translational science, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Sarah J SchlesingerCenter for Clinical and Translational Science, Rockefeller University, New York, NY, USA.
Michelle RomanickCenter for Clinical and Translational Science, Rockefeller University, New York, NY, USA.
Jonathan N TobinCenter for Clinical and Translational Science, Rockefeller University, New York, NY, USA.
Donna BrassilCenter for Clinical and Translational Science, Rockefeller University, New York, NY, USA.
Rhonda G KostCenter for Clinical and Translational Science, Rockefeller University, New York, NY, USA.
Rita DevineCenter for Clinical and Translational Science, Rockefeller University, New York, NY, USA.
Barbara O'SullivanCenter for Clinical and Translational Science, Rockefeller University, New York, NY, USA.
Roger D VaughanCenter for Clinical and Translational Science, Rockefeller University, New York, NY, USA.
Yupu LiangCenter for Clinical and Translational Science, Rockefeller University, New York, NY, USA.
Joel Correa da RosaCenter for Clinical and Translational Science, Rockefeller University, New York, NY, USA.
Maija WilliamsCenter for Clinical and Translational Science, Rockefeller University, New York, NY, USA.
James G KruegerCenter for Clinical and Translational Science, Rockefeller University, New York, NY, USA.
Barry S CollerCenter for Clinical and Translational Science, Rockefeller University, New York, NY, USA.

Funding

Developing, Demonstrating, and Disseminating Innovative Programs to Achieve Translational SuccessUL1TR001866 · NCATS · ROCKEFELLER UNIVERSITY · PI COLLER, BARRY, KRUEGER, JAMES G · 2016 to 2025
$40.6M
Institutional Career Development CoreKL2TR001865 · NCATS · ROCKEFELLER UNIVERSITY · PI SCHLESINGER, SARAH JANE · 2016 to 2025
$8.7M
Transforming Translational Science and Education to Benefit Human HealthKL2TR000151 · NCATS · ROCKEFELLER UNIVERSITY · PI COLLER, BARRY · 2012 to 2015
$2.1M
NCATS NIH HHS KL2 TR000151NCATS NIH HHS KL2 TR001865NCATS NIH HHS UL1 TR001866
6 · The paper itself

Abstract

INTRODUCTION AND

methodsThe Rockefeller Clinical Scholars (KL2) Program began in 1976 and transitioned into a 3-year Master's degree program in 2006 when Rockefeller joined the NIH Clinical and Translational Science Award (CTSA) program. The program consists of ~15 trainees supported by the CTSA KL2 award and University funds. It is designed to provide an optimal environment for junior translational investigators to develop team science and leadership skills by designing and performing a human subjects protocol under the supervision of a distinguished senior investigator mentor and a team of content expert educators. This is complemented by a tutorial focused on important translational skills.

resultsSince 2006, 40 Clinical Scholars have graduated from the programs and gone on to careers in academia (72%), government service (5%), industry (15%), and private medical practice (3%); two (5%) remain in training programs. 39/40 remain in translational research careers with 23 NIH awards totaling $23 million, foundation and philanthropic support of $20.3 million, and foreign government and foundation support of $6 million. They have made wide ranging scientific discoveries and have endeavored to translate those discoveries into improved human health.

conclusionThe Rockefeller Clinical Scholars (KL2) program provides one model for translational science training.

Indexed as

KL2Master’s DegreeTrainingTranslational Research

Identifiers

PMID29456873
PMCPMC5812696

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.